Corrigendum to "Suppression of experimental autoimmune myasthenia gravis by combination therapy: Pentoxifylline as a steroid-sparing agent" [J. Neuroimmunol. 201-202 (2008) 128-135] (DOI:10.1016/j.jneuroim.2008.05.023)

Renuka T.R. Menon, Tali Feferman, Revital Aricha, Miriam C. Souroujon, Sara Fuchs

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)129
Number of pages1
JournalJournal of Neuroimmunology
Issue number1-2
StatePublished - 30 Oct 2009

Bibliographical note

Funding Information:
This research was supported by grants from The Muscular Dystrophy Association of America (MDA), The Association Francaise Cortre les Myopathies (AFM), The European Commission (EC, No QLG1-CT-2001-10918, QLRT-2001-00225 and LSHN-CT-2006-037833) and The Chief Scientist Office, Israel Ministry of Health.

Cite this